about
Treatment Options for EGFR T790M-Negative EGFR Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer.Biomarkers of Primary Resistance to Trastuzumab in HER2-Positive Metastatic Gastric Cancer Patients: the AMNESIA Case-Control Study.Prognostic impact of ATM mutations in patients with metastatic colorectal cancerAssessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trialTemozolomide and irinotecan (TEMIRI regimen) as salvage treatment of irinotecan-sensitive advanced colorectal cancer patients bearing MGMT methylationPerioperative Bevacizumab-based Triplet Chemotherapy in Patients With Potentially Resectable Colorectal Cancer Liver MetastasesRefining the selection of patients with metastatic colorectal cancer for treatment with temozolomide using proteomic analysis of O6-methylguanine-DNA-methyltransferaseCapecitabine and Temozolomide versus FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal CancerMetronomic Capecitabine With Cyclophosphamide Regimen in Unresectable or Relapsed Pseudomyxoma PeritoneiMaintenance Therapy With Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients With RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical TrialClinical Behavior and Treatment Response of Epstein-Barr Virus-Positive Metastatic Gastric Cancer: Implications for the Development of Future TrialsLack of Benefit From Anti-EGFR Treatment in RAS and BRAF Wild-type Metastatic Colorectal Cancer With Mucinous Histology or Mucinous ComponentClass 1, 2, and 3 BRAF-Mutated Metastatic Colorectal Cancer: A Detailed Clinical, Pathologic, and Molecular CharacterizationAssociation of high TUBB3 with resistance to adjuvant docetaxel-based chemotherapy in gastric cancer: translational study of ITACA-S
P50
Q39131033-8EFBB2E7-0D9A-4039-A79B-ADF090B7F318Q50058854-BE31728F-31F2-4752-9A2C-890B9D1FAE5BQ64097897-7F2D0430-4C84-471B-83A8-8ACA47E5FF73Q64100971-3D3D2153-223F-491B-87CA-0F61E1D7E819Q88961041-A1A31A5E-27FF-4678-B700-65A7FB29362FQ90592695-CBCFF038-74AB-4298-83A0-F39A8182DF86Q90716197-A7B542E4-3F9D-4C02-9CE4-A7BC9858D56FQ91329177-5A54257F-EEDF-46BF-B178-6D8E14051F2FQ91520236-C2277DD5-6C74-476C-BA8C-E25D9C52A5F3Q91577603-F7FF81A8-2CBC-4264-B74A-2861FA322DB5Q91775269-31545C5A-5201-4D94-8D22-966EE9A21BC9Q92883841-89BA4C31-A769-466B-98A7-F3C0B32D685AQ92985775-B4FE6CC0-10CE-4514-9164-7B0D5CFD13ADQ96296951-BE646FC9-E2EB-45A3-BDB0-7FE39D1463E7
P50
description
researcher
@en
wetenschapper
@nl
name
S Corallo
@en
S Corallo
@nl
type
label
S Corallo
@en
S Corallo
@nl
prefLabel
S Corallo
@en
S Corallo
@nl
P31
P496
0000-0002-6672-0233